News

Study OverviewBrief SummaryThis study intends to conduct a prospective observation to investigate the prevalence of cardiac amyloidosis (CA) in patients with aortic…

As per DataM intelligence research report "The global transthyretin amyloid cardiomyopathy (ATTR-CM) was valued at US$ 2.92 Billion n 2023. The global transthyretin…

A new study published in Open Heart provided up-to-date data on the epidemiology of amyloid transthyretin (ATTR) amyloidosis in the US. “Our findings…

AbstractAmyloidosis is a group of disorders caused by extracellular deposition of insoluble fibrillar proteins, leading to progressive organ dysfunction. Cardiac…

Bayer, a global leader in radiology and cardiology, has struck a major deal to acquire two investigational molecular imaging agents from clinical-stage…

Prof. Liu Cong from the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences, along with collaborators, has revealed the high-resolution…

There has been an uptick in volume in recent years for cardiac amyloidosis imaging. Securing an early diagnosis of the disease is crucial to initiate drug treatment…

Not intended for UK MediaBayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance…

Bayer, looking to bolster its position in both imaging and cardiac medicine, struck a deal to snap up two experimental imaging agents and thereby enter the…

The number of people diagnosed with transthyretin amyloidosis (ATTR) in the U.S. is climbing, a surge researchers attribute to better medical awareness and more…